Omeros (OMER) Competitors

$13.30 -1.08 (-7.48%)

As of 03:52 PM Eastern

OMER vs. NKTR, SUPN, PRGO, PCRX, and ASMB

Should you buy Omeros stock or one of its competitors? MarketBeat compares Omeros with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Omeros include Nektar Therapeutics (NKTR), Supernus Pharmaceuticals (SUPN), Perrigo (PRGO), Pacira BioSciences (PCRX), and Assembly Biosciences (ASMB). These companies are all part of the "pharmaceuticals" industry.

How does Omeros compare to Nektar Therapeutics?

Omeros (NASDAQ:OMER) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Omeros currently has a consensus target price of $40.33, indicating a potential upside of 202.21%. Nektar Therapeutics has a consensus target price of $149.63, indicating a potential upside of 102.08%. Given Omeros' stronger consensus rating and higher probable upside, research analysts plainly believe Omeros is more favorable than Nektar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Omeros' return on equity of -72.14% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-72.14%	59.71%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

Omeros has a beta of 2.66, meaning that its share price is 166% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Omeros has higher earnings, but lower revenue than Nektar Therapeutics. Omeros is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	-$0.50	N/A
Nektar Therapeutics	$55.23M	45.30	-$164.08M	-$8.42	N/A

In the previous week, Nektar Therapeutics had 16 more articles in the media than Omeros. MarketBeat recorded 26 mentions for Nektar Therapeutics and 10 mentions for Omeros. Omeros' average media sentiment score of 0.85 beat Nektar Therapeutics' score of 0.43 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

48.8% of Omeros shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 12.9% of Omeros shares are held by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Omeros beats Nektar Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Omeros compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Omeros (NASDAQ:OMER) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Omeros has lower revenue, but higher earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$776.83M	3.82	-$38.55M	-$0.51	N/A
Omeros	N/A	N/A	-$3.35M	-$0.50	N/A

Supernus Pharmaceuticals presently has a consensus price target of $62.17, indicating a potential upside of 21.59%. Omeros has a consensus price target of $40.33, indicating a potential upside of 202.21%. Given Omeros' stronger consensus rating and higher probable upside, analysts plainly believe Omeros is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

48.8% of Omeros shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 12.9% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Omeros has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Omeros	N/A	-72.14%	59.71%

Supernus Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market. Comparatively, Omeros has a beta of 2.66, indicating that its stock price is 166% more volatile than the broader market.

In the previous week, Omeros had 7 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 10 mentions for Omeros and 3 mentions for Supernus Pharmaceuticals. Omeros' average media sentiment score of 0.85 beat Supernus Pharmaceuticals' score of 0.83 indicating that Omeros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omeros	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Omeros beats Supernus Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Omeros compare to Perrigo?

Perrigo (NYSE:PRGO) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

95.9% of Perrigo shares are held by institutional investors. Comparatively, 48.8% of Omeros shares are held by institutional investors. 0.4% of Perrigo shares are held by company insiders. Comparatively, 12.9% of Omeros shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Omeros	N/A	-72.14%	59.71%

Perrigo presently has a consensus target price of $19.33, indicating a potential upside of 77.73%. Omeros has a consensus target price of $40.33, indicating a potential upside of 202.21%. Given Omeros' stronger consensus rating and higher probable upside, analysts plainly believe Omeros is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Omeros has lower revenue, but higher earnings than Perrigo. Omeros is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.18B	0.36	-$1.43B	-$13.10	N/A
Omeros	N/A	N/A	-$3.35M	-$0.50	N/A

Perrigo has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, Omeros has a beta of 2.66, indicating that its stock price is 166% more volatile than the broader market.

In the previous week, Omeros had 8 more articles in the media than Perrigo. MarketBeat recorded 10 mentions for Omeros and 2 mentions for Perrigo. Omeros' average media sentiment score of 0.85 beat Perrigo's score of 0.54 indicating that Omeros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Omeros	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Omeros beats Perrigo on 12 of the 16 factors compared between the two stocks.

How does Omeros compare to Pacira BioSciences?

Omeros (NASDAQ:OMER) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Pacira BioSciences has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	-$0.50	N/A
Pacira BioSciences	$734.86M	1.26	$7.03M	$0.12	196.25

Pacira BioSciences has a net margin of 0.70% compared to Omeros' net margin of 0.00%. Pacira BioSciences' return on equity of 10.24% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-72.14%	59.71%
Pacira BioSciences	0.70%	10.24%	5.47%

48.8% of Omeros shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 12.9% of Omeros shares are held by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Omeros currently has a consensus target price of $40.33, suggesting a potential upside of 202.21%. Pacira BioSciences has a consensus target price of $29.40, suggesting a potential upside of 24.84%. Given Omeros' stronger consensus rating and higher probable upside, equities research analysts plainly believe Omeros is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Pacira BioSciences had 2 more articles in the media than Omeros. MarketBeat recorded 12 mentions for Pacira BioSciences and 10 mentions for Omeros. Omeros' average media sentiment score of 0.85 beat Pacira BioSciences' score of 0.55 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacira BioSciences	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omeros has a beta of 2.66, indicating that its share price is 166% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Summary

Pacira BioSciences beats Omeros on 9 of the 16 factors compared between the two stocks.

How does Omeros compare to Assembly Biosciences?

Omeros (NASDAQ:OMER) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Omeros has a net margin of 0.00% compared to Assembly Biosciences' net margin of -8.98%. Assembly Biosciences' return on equity of -4.21% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-72.14%	59.71%
Assembly Biosciences	-8.98%	-4.21%	-3.14%

48.8% of Omeros shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 12.9% of Omeros shares are held by insiders. Comparatively, 5.3% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Omeros has higher earnings, but lower revenue than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	-$0.50	N/A
Assembly Biosciences	$72.30M	6.63	-$6.12M	-$0.11	N/A

Omeros has a beta of 2.66, suggesting that its stock price is 166% more volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

Omeros presently has a consensus target price of $40.33, suggesting a potential upside of 202.21%. Assembly Biosciences has a consensus target price of $42.75, suggesting a potential upside of 41.64%. Given Omeros' stronger consensus rating and higher possible upside, analysts clearly believe Omeros is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Assembly Biosciences had 2 more articles in the media than Omeros. MarketBeat recorded 12 mentions for Assembly Biosciences and 10 mentions for Omeros. Omeros' average media sentiment score of 0.85 beat Assembly Biosciences' score of 0.62 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Assembly Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Omeros beats Assembly Biosciences on 11 of the 16 factors compared between the two stocks.

Get Omeros News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMER vs. The Competition

Export

Metric	Omeros	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$962.32M	$7.98B	$6.29B	$12.46B
Dividend Yield	N/A	2.50%	2.79%	5.30%
P/E Ratio	-26.67	18.38	20.85	25.56
Price / Sales	N/A	7.76	543.57	72.25
Price / Cash	7.89	16.76	42.94	55.34
Price / Book	-7.80	3.68	9.87	6.72
Net Income	-$3.35M	$223.05M	$3.55B	$333.62M
7 Day Performance	-9.12%	-1.79%	-0.23%	0.35%
1 Month Performance	12.37%	3.57%	1.47%	4.00%
1 Year Performance	238.55%	1.91%	41.05%	36.32%

Omeros Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMER Omeros	3.3344 of 5 stars	$13.35 -7.2%	$40.33 +202.2%	+224.6%	$962.32M	N/A	N/A	210	News Coverage Earnings Report Analyst Forecast High Trading Volume
NKTR Nektar Therapeutics	3.1771 of 5 stars	$86.89 +0.5%	$140.63 +61.8%	+613.2%	$2.92B	$55.23M	N/A	220	Trending News Earnings Report Analyst Forecast Analyst Revision
SUPN Supernus Pharmaceuticals	3.1242 of 5 stars	$48.63 +1.6%	$62.17 +27.8%	+59.1%	$2.76B	$718.95M	N/A	580	High Trading Volume
PRGO Perrigo	4.2528 of 5 stars	$11.39 -4.5%	$19.33 +69.8%	-58.3%	$1.64B	$4.25B	N/A	8,100
PCRX Pacira BioSciences	3.1885 of 5 stars	$24.69 +1.0%	$29.40 +19.1%	-1.5%	$961.35M	$726.41M	205.77	720	News Coverage Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMER) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omeros (OMER) Competitors

OMER vs. NKTR, SUPN, PRGO, PCRX, and ASMB

How does Omeros compare to Nektar Therapeutics?

Summary

How does Omeros compare to Supernus Pharmaceuticals?

Summary

How does Omeros compare to Perrigo?

Summary

How does Omeros compare to Pacira BioSciences?

Summary

How does Omeros compare to Assembly Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMER vs. The Competition

Omeros Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omeros (OMER) Competitors

OMER vs. NKTR, SUPN, PRGO, PCRX, and ASMB

How does Omeros compare to Nektar Therapeutics?

Do analysts recommend OMER or NKTR?

Is OMER or NKTR more profitable?

Which has more volatility and risk, OMER or NKTR?

Which has better earnings & valuation, OMER or NKTR?

Does the media favor OMER or NKTR?

Do insiders and institutionals have more ownership in OMER or NKTR?

Summary

How does Omeros compare to Supernus Pharmaceuticals?

Which has stronger valuation & earnings, SUPN or OMER?

Do analysts recommend SUPN or OMER?

Do insiders & institutionals have more ownership in SUPN or OMER?

Is SUPN or OMER more profitable?

Which has more risk and volatility, SUPN or OMER?

Does the media prefer SUPN or OMER?

Summary

How does Omeros compare to Perrigo?

Do insiders & institutionals believe in PRGO or OMER?

Is PRGO or OMER more profitable?

Do analysts prefer PRGO or OMER?

Which has preferable earnings & valuation, PRGO or OMER?

Which has more risk & volatility, PRGO or OMER?

Does the media favor PRGO or OMER?

Summary

How does Omeros compare to Pacira BioSciences?

Which has better valuation and earnings, OMER or PCRX?

Is OMER or PCRX more profitable?

Do institutionals and insiders have more ownership in OMER or PCRX?

Do analysts rate OMER or PCRX?

Does the media prefer OMER or PCRX?

Which has more volatility and risk, OMER or PCRX?

Summary

How does Omeros compare to Assembly Biosciences?

Is OMER or ASMB more profitable?

Do institutionals and insiders believe in OMER or ASMB?

Which has preferable valuation & earnings, OMER or ASMB?

Which has more volatility & risk, OMER or ASMB?

Do analysts prefer OMER or ASMB?

Does the media refer more to OMER or ASMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMER vs. The Competition

Omeros Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools